{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:54:01Z","timestamp":1787504041375,"version":"build-2736575974"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Montfort Hospital","award":["24-25-10-036"],"award-info":[{"award-number":["24-25-10-036"]}]},{"award":["24-25-10-036"],"award-info":[{"award-number":["24-25-10-036"]}],"id":[{"id":"https:\/\/ror.org\/02crzj551","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Achieving and maintaining therapeutic anticoagulation with unfractionated heparin in critically ill patients is challenging due to biologic variability, heparin resistance, and limitations of activated partial thromboplastin time (aPTT) monitoring. Argatroban, a direct thrombin inhibitor, provides antithrombin-independent anticoagulation with more predictable pharmacokinetics, but real-world data describing its anticoagulation stability in the intensive care unit (ICU) remain limited. Objective: This study aimed to compare anticoagulation stability between continuous intravenous argatroban and unfractionated heparin in critically ill patients using time in therapeutic range (TTR) based on aPTT as the primary performance metric. Methods: A retrospective cohort study was conducted in the ICU and step-down unit of H\u00f4pital Montfort (Ottawa, ON, Canada) between January 2016 and December 2024. Adult patients receiving continuous intravenous argatroban or unfractionated heparin for systemic anticoagulation were included. All aPTT values obtained during active infusion were extracted, and TTR was calculated using linear interpolation between consecutive measurements. Continuous variables were summarized as medians with interquartile ranges and compared using the Wilcoxon rank-sum test; categorical TTR strata were compared using Fisher\u2019s exact test. Results: Sixty-eight patients met the inclusion criteria, contributing 9 argatroban and 61 heparin infusion courses. Argatroban demonstrated a higher median TTR than heparin (83.3% [IQR 82.0\u201390.7] vs. 47.5% [32.9\u201362.4]; p &lt; 0.001), with a moderate-to-large effect size (r = 0.51). Median aPTT values were similar between groups, but argatroban showed narrower dispersion and fewer prolonged subtherapeutic periods. A majority of heparin courses (56.5%) spent &lt;50% of time within range, whereas no argatroban courses fell into this category. Conversely, 33.3% of argatroban courses achieved \u226590% TTR compared with none in the heparin group. Conclusions: In this real-world ICU cohort where argatroban was used for suspected or confirmed HIT, argatroban was associated with higher TTR than unfractionated heparin. These findings support the use of time-dependent metrics to evaluate anticoagulation quality and warrant prospective studies in more homogeneous populations.<\/jats:p>","DOI":"10.3390\/hematolrep18030031","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:50:01Z","timestamp":1777618201000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1616-6641","authenticated-orcid":false,"given":"Imran","family":"Khan","sequence":"first","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lamarche","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Hendin","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4484-9136","authenticated-orcid":false,"given":"Andy","family":"Pan","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Richler","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-1147","authenticated-orcid":false,"given":"Christine","family":"Landry","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Morin","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4128-8286","authenticated-orcid":false,"given":"Kaouther","family":"Derouiche","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-0228","authenticated-orcid":false,"given":"Pierre","family":"Thabet","sequence":"additional","affiliation":[{"name":"Montfort Hospital, Ottawa, ON K1K 0T2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMra2104091","article-title":"Heparin Resistance\u2014Clinical Perspectives and Management Strategies","volume":"385","author":"Levy","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/hematology.2024000659","article-title":"Troubleshooting heparin resistance","volume":"2024","author":"Maier","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1160\/TH15-11-0847","article-title":"Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia","volume":"115","author":"Keyl","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_9","unstructured":"Baxter Healthcare Corporation (2024). Argatroban Injection: Full Prescribing Information [Internet]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","first-page":"305","article-title":"Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin","volume":"72","author":"Middeldorp","year":"2014","journal-title":"Neth. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12630-019-01391-y","article-title":"Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient","volume":"66","author":"Downie","year":"2019","journal-title":"Can. J. Anaesth."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/20009666.2018.1466599","article-title":"To be or not to be a case of heparin resistance","volume":"8","author":"Durrani","year":"2018","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10760296231205279","DOI":"10.1177\/10760296231205279","article-title":"Antithrombin Therapy: Current State and Future Outlook","volume":"29","author":"Rodgers","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:16:20Z","timestamp":1778818580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["hematolrep18030031"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18030031","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}